A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations
Trial Details
- NCT ID
- NCT06644768
- Phase
- PHASE1 / PHASE2
- Sponsor
- Daiichi Sankyo
- Status
- RECRUITING
- Cancer Type
- Lung Cancer
- Interventions
- valemetostat tosylate
- pembrolizumab
- Locations (sample)
- La Jolla, California, United States|32.84727,-117.2742
- Los Angeles, California, United States|34.05223,-118.24368
- Los Angeles, California, United States|34.05223,-118.24368
- Jacksonville, Florida, United States|30.33218,-81.65565
- Plantation, Florida, United States|26.13421,-80.23184
Key Eligibility Criteria
- Has signed and dated the ICF, prior to the start of any trial-specific qualification procedures.
- Is an adult ≥18 years of age or the minimum legal age (whichever is greater) at the time of informed consent. (Follow local regulatory requirements…
- Has histologically documented NSCLC that meets all of the following criteria:
- Has no prior systemic therapy for advanced or metastatic disease.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lung Cancer Trials on Trialify →